Literature DB >> 22908177

eComment. The vraisemblance of haemostatic therapy for excessive bleeding after cardiac surgery.

Kelechi E Okonta1, Emeka B Kesieme, Vijay Agarwal.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22908177      PMCID: PMC3422974          DOI: 10.1093/icvts/ivs307

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


× No keyword cloud information.
  5 in total

1.  Use of prothrombin complex concentrate for excessive bleeding after cardiac surgery.

Authors:  Vrigina Arnékian; Julien Camous; Soly Fattal; Saida Rézaiguia-Delclaux; Rémi Nottin; François Stéphan
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-05-23

2.  Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy.

Authors:  Henry Ekert; Christian Brizard; Robert Eyers; Andrew Cochrane; Robert Henning
Journal:  Blood Coagul Fibrinolysis       Date:  2006-07       Impact factor: 1.276

3.  Re-exploration after open heart surgery at the madras medical mission, chennai, India.

Authors:  Ke Okonta; S Rajan
Journal:  J West Afr Coll Surg       Date:  2011-04

4.  Recombinant activated factor VII following pediatric cardiac surgery.

Authors:  Sharmila Kylasam; Krista Mos; Stephanie Fijtin; Boyd Webster; Richard Chard; Jonathan Egan
Journal:  J Intensive Care Med       Date:  2009-02-02       Impact factor: 3.510

5.  The use of recombinant coagulation factor VIIa in uncontrolled postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass.

Authors:  Magdalena Pychyńska-Pokorska; Jacek Jan Moll; Wojciech Krajewski; Piotr Jarosik
Journal:  Pediatr Crit Care Med       Date:  2004-05       Impact factor: 3.624

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.